Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); high definition qualitative panel for identification of antibody specificities (eg, individual antigen per bead methodology), HLA Class II
CPT4 code
Name of the Procedure:
Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, Flow cytometry); high definition qualitative panel for identification of antibody specificities, HLA Class II
- Common Name: HLA Antibody Testing
- Technical Term: HLA Class II Antibody Identification Assay
Summary
HLA antibody testing involves analyzing a patient's blood sample to identify specific antibodies against human leukocyte antigens (HLA). These antibodies are detected through advanced laboratory techniques that use microspheres, beads, ELISA, or flow cytometry.
Purpose
- Addressing the risk of transplant rejection by identifying antibodies that could attack a donated organ.
- Guiding treatment decisions for conditions like autoimmune diseases.
- Improving compatibility assessment between donors and recipients in organ or tissue transplantation.
Indications
- People being evaluated for organ or tissue transplantation.
- Patients with a history of transplant rejection.
- Individuals with autoimmune diseases or certain unexplained immune reactions.
Patients preparing for treatments such as stem cell therapy.
Preparation
- No special preparation is usually required.
- Patients should inform their healthcare provider about any medications they are taking.
- A blood sample is typically taken (fasting is not necessary unless specified by the doctor).
Procedure Description
- Blood Sample Collection: A small amount of blood is drawn from a vein in the arm.
- Laboratory Processing: The blood sample is sent to a lab where the serum is separated.
- Assay Execution:
- In microsphere/beads and ELISA methods, the serum is exposed to HLA-coated beads or plates to detect binding antibodies.
- Flow cytometry involves labeling antibodies with fluorescent markers to analyze them in a specialized machine.
- Data Analysis: The presence and specificity of antibodies are identified and recorded for further clinical decision-making.
Duration
The blood draw takes about 10-15 minutes. Laboratory analysis can take several hours to a few days to complete.
Setting
The blood sample is usually drawn in a clinic, doctor's office, or hospital. The analysis itself is performed in a specialized laboratory.
Personnel
- Phlebotomist or nurse to collect the blood sample.
- Lab technicians and medical technologists to analyze the sample.
- Pathologists or immunologists to interpret the results.
Risks and Complications
- Common Risks: Minor pain or bruising at the blood draw site.
- Rare Risks: Infection or excessive bleeding at the draw site.
Benefits
- Expected Benefits:
- Precise identification of HLA antibodies.
- Enhanced matching between organ/tissue donors and recipients.
- Improved outcomes and reduced risk of transplant rejection.
- Realization Time: Results contribute immediately to clinical decisions once analysis is complete.
Recovery
- Post-Procedure Care: Minimal care required at the blood draw site (e.g., applying pressure, keeping the site clean).
- Recovery Time: Immediate; no downtime required.
- Restrictions: None, unless other tests or treatments are scheduled.
Alternatives
- Other Options:
- Cellular assays (e.g., complement-dependent cytotoxicity assays)
- Crossmatch tests between donor and recipient tissue samples.
- Comparison: Alternative tests may be less precise or slower, but can still provide useful information in different clinical contexts.
Patient Experience
- During the Procedure: The patient will experience a brief pinch or sting from the needle during blood draw.
- After the Procedure: Slight tenderness or bruising at the puncture site; easily manageable with over-the-counter pain relief if necessary. Comfort measures such as applying a cold pack to reduce any swelling.